Good day everyone and welcome to Aflac’s third quarter 2020 earnings call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press the pound key. Thank you. I would now like to turn the call over to your host, David Young, Vice President of Aflac Incorporated Investor Relations. Please go ahead, sir.

Thank you Adrienne. Good morning and welcome to Aflac Incorporated’s third quarter earnings call. As always, we have posted our earnings release and financial supplement to investors.aflac.com. This morning, we will be hearing remarks about the quarter as well as our operations in Japan and the United States amid the COVID-19 pandemic. Dan Amos, Chairman and CEO of Aflac Incorporated will begin with an overview of our operations in Japan and the U.S. Fred Crawford, President and COO of Aflac Incorporated will then touch briefly on conditions in the third quarter and discuss how we are navigating the pandemic, including some key initiatives. Max Broden, Executive Vice President and CFO of Aflac Incorporated will then conclude our prepared remarks with a summary of third quarter financial results and current capital and liquidity. Joining us this morning during the Q&A portion are members of our executive management team in the U.S.: Teresa White, President of Aflac U.S., Eric Kirsch, Global Chief Investment Officer and President of Aflac Global Investments; Rich Williams, Chief Distribution Officer; Al Riggieri, Global Chief Risk Officer and Chief Actuary; June Howard, Chief Accounting Officer, and Steve Beaver, CFO of Aflac U.S. We are also joined by members of our executive management team in Tokyo at Aflac Life Insurance Japan: Charles Lake, Chairman and representative Director, President of Aflac International; Masatoshi Koide, President and representative Director; Todd Daniels, Director and CFO; and Koji Ariyoshi, Director and Head of Sales and Marketing. Before we begin, some statements in this teleconference are forward-looking within the meaning of federal securities laws. Although we believe these statements are reasonable, we can give no assurance that they will prove to be accurate because they are prospective in nature. Actual results could differ materially from those we discuss today. We encourage you to look at our annual report on Form 10-K for some of the various risk factors that could materially impact our results. As I mentioned earlier, the earnings release is available on investors.aflac.com and includes reconciliations to certain non-U.S. GAAP measures. I’ll now hand the call over to Dan. Dan?

Thank you David, and good morning. Thanks for joining us. As we all know, the COVID-19 pandemic has ushered in some of the most difficult times for so many people around the globe, and we continue to pray for all those affected. I’d like to share my appreciation for our employees and sales force in Japan and the United States for their tireless work in helping our policyholders and communities impacted by the pandemic. During this difficult time, it’s important to note that we remain focused on doing what we do best, that is providing protective products to help consumers when they need it most. This morning, I’ll provide an overview of the quarter and how we performed by operating segment. Financially, Aflac continues to be impacted by the pandemic but remains strong in terms of capital and liquidity. In addition, our investments are high quality and diversified, and they are among the highest return on capital and lowest cost of capital in the industry. Amid the challenges of COVID-19, this quarter was also significantly impacted by the release of favorable U.S. tax regulations related to the utilization of foreign tax credits. You will recall that our Japanese subsidiary is taxed as a U.S. domestic company for U.S. tax purposes. In the quarter, we recognized a cumulative year to date benefit from these regulations of $202 million, or $0.28 per share compared to our previous run rate. Max will provide additional details. Turning to our operations, starting with Aflac Japan, the effect of COVID-19 continues to noticeably impact our results, as seen in the third quarter with sales decreasing 32%. We continued to have around 50% of the workforce working from home in Japan and in September, traffic coming into the shops remained at 70% of pre-pandemic levels. While these…

Thank you Dan. I’m going to touch briefly on conditions in the third quarter and how we’re navigating the pandemic. I’ll also provide an update on key initiatives in Japan and the U.S. to include our approach to managing expenses. There are currently approximately 97,000 COVID-19 cases and 1,730 deaths in all of Japan. Through the third quarter, Aflac Japan COVID-19 impact totaled 1,750 unique claimants with incurred claims totaling approximately ¥550 million in the quarter and ¥760 million year to date. In short, we are tracking well below our stress assumptions with no measurable impact from COVID-19 claims; however, reduced sales and delaying the promotion of the new cancer rider and refreshed medical product are contributing to revenue pressure. This pressure is offset somewhat by favorable persistency. COVID-related expenses in the quarter totaled ¥1.7 billion, which included the rollout of virtual distribution tools, employee teleworking equipment, and distribution support. In the U.S., the dynamics are understandably more complex. COVID-19 case levels in the U.S. now exceed 8.5 million with deaths nearly 230,000. Through the end of the third quarter, COVID-19 claimants in the U.S. totaled 12,800 with incurred claims of approximately $23 million in the quarter and year to date approximately $57 million. We are closely monitoring the recent surge in infections but continue to see the rate of hospitalization, length of stay in the hospital, and transition to ICU traveling below our expectations. We believe this is attributed to advancements in treatment and the nature of the worksite, which is a generally younger and healthier population of policyholders. As Dan noted in his comments, we launched an initiative early in the third quarter to remind policyholders of their wellness benefits, which drove increased utilization. This effort involved connecting with 2.7 million accident and hospital policyholders through a combination…

Thank you Fred. Let me begin my comments with a review of our third quarter performance with a focus on how our core capital and earnings drivers have developed. For the third quarter, adjusted earnings per share increased 19.8% to $1.39 with no significant impact from FX in the quarter. Adjusted book value per share, including foreign currency translation gains and losses, grew 17.4% and the adjusted ROE, excluding the foreign currency impact, was a strong 16.8%, a material spread to our cost of capital. This quarter was significantly impacted by the release of favorable U.S. tax regulations related to the utilization of foreign tax credits. As a reminder, our Japanese subsidiary is taxed as a U.S. domestic company for U.S. tax purposes. In the quarter, we recognized a cumulative year-to-date benefit from these regulations which lowered our tax rate on adjusted earnings for the quarter to 4.1%, a benefit of $0.28 versus our previous run rate. Our tax rate for the quarter further benefited from tax credits in our solar and historic rehabilitation investments which lowered our tax expense by approximately $20 million more than in a normal quarter. In addition, variable investment income came in $6 million above our long-term return expectations, and together these two items boosted current quarter EPS by about $0.03. On a go forward basis and under the current U.S. corporate tax regime, we would expect our go forward tax rate on adjusted earnings to be approximately 20%. Turning to our Japan segment, total earned premium for the quarter declined 3.3%, reflecting mainly first sector policies paid up impacts, while earned premium put at third sector product was down 1.7%. Japan’s revenue trend should be considered in light of impact of paid-up policies. For example, year-over-year earned premium was down 3.3% in the quarter…

Thank you Max. We’re now ready to take your questions, but first let me ask you to please limit yourselves to one initial question, followed by a related follow-up question to allow other participants an opportunity to ask a question. Adrienne, we will now take that first question.

Your first question comes from the line of Nigel Dally with Morgan Stanley.

Great, thanks, and good morning everyone. My question is on expenses. You announced the U.S. expense reduction initiative together with the paperless initiative in Japan, but you’re also talking about ramping higher investments in other digital and growth initiatives. Appreciate the color for the fourth quarter, but how should we be thinking about expense ratios in 2021? Should we see the benefit of those initiatives flow through to the bottom line or still elevated expense ratios looking forward?

Nigel, this is Fred. I would say in general, both in the case of the U.S. as well as Japan in 2021, you should anticipate a continuation of elevated expenses as these investments will continue at their current pace. In fact in the U.S., we will particularly be building more proactively on the dental and vision, the consumer markets, and then now adding the group benefits business, so you’ll see the pace of investment improve. When it comes to business as usual expenses, or what we would call our general operating expenses, that’s where you’ll see improvement particularly in the U.S. as we take action around staffing models, headcount and other related cost savings efforts, so it’s a balancing act. We’ll give more color on our expense ratios, both in Japan and the U.S., at the financial analyst briefing as we traditionally do, so I don’t want to get out in front of that; but I can certainly answer your question that the pace of investment will continue to go forward but it’s really directed towards growth, as well as efficiency. Remember there’s two components to the expense ratio, and one of the things weighing on our expense ratios right now in Japan and the U.S. is weakness in revenue, so we’ve got to drive these expenses through to generate revenue improvement over time. That will be the path to victory on expense ratios ultimately.

Very helpful, thank you.

Your next question comes from the line of Jimmy Bhullar with JP Morgan Securities LLC.

Hi, good morning. I had a question just on the U.S. business. Obviously sales have been pretty weak recently, and I’m assuming that 4Q will be a little bit better just given that a majority of the sales are broker sales and that channel doesn’t seem to be as impacted by social distancing and stuff. But what’s your path to an improvement in sales beyond that, because I’m assuming even though businesses are starting to open up, most of them are going to be reluctant to have salespeople come in and pitch products or [indiscernible] people, so what’s--like, just a few comments on what you feel is going to drive recovery in your sales in the U.S. beyond just a vaccine or normalization of social and business trends?

I’m going to have Richard answer that.

Okay, thank you Jimmy. As Dan noted in his comments, we expect modest sequential improvement in the fourth quarter compared to the second and the third quarter, and as you recall, the fourth quarter for us is more heavily weighted to broker sales, roughly about 50% of our quarter. That’s where less face-to-face enrollment is utilized as well as larger cases, so I think those are the support points to Dan’s comments around modest sequential improvement. I think secondly, we will reserve comment around 2021 for our outlook call and financial analyst briefing, and we look forward to that discussion then.

Teresa, do you want to add anything?

No, I think Rich covered it. Thank you.

Maybe just another one on the U.S. on your persistency. Can you talk about what you’ve seen in terms of persistency in the regions where premium grace periods have expired? Are you seeing an uptick in lapses there, or not?

Overall we have not seen a notable increase in policy lapses given the stability in our persistency rates, but we continue to monitor especially with the small business side. It’s important to note that small business is a large part of our in force; however, the premium is more balanced across small and large cases, so really we’re not seeing what we thought we would see, but we’re continuing to monitor this and we’ll give more insight at the investor conference as well.

And I think the wellness benefit and our ability to pay claims for it, although it kicked up our benefit ratio which we wanted to happen, we believe it will also have a positive impact on persistency as people realize they need the product.

Thanks.

The next question comes from the line of Suneet Kamath with Citi.

Thanks, good morning. I think you had said you expect some new products in Japan in the first quarter, so just curious - normally when you launch a new product, we see an almost immediate pick-up in sales. Just given the pandemic and how the sales dynamic has changed, should we expect the same sort of trend that we’ve seen historically, and will you be selling this new medical product in the Japan--sorry, the cancer product in the Japan closed channel?

Koide?

Koji will answer that question.

[translated from Japanese] In terms of medical insurance, as we have already started with our cancer insurance, we have implemented web certification as well as application--insurance application system, from October, and this will allow reduction of COVID-19 risk, like having social distance. On top of that, this medical insurance product that we plan to launch is a competitive product, so we will be able to win in the competition, and that way we should be able to increase our share in the medical market. Our new product has a broad range of coverage to really be able to respond to various types of customers. For example, a lot of the customers have concerns about the three dread diseases, which we will cover further in this new product, as well as short term coverage in the medical insurance, and at the same time those customers who really do not want to just keep on paying premium and gain nothing, we do have some no-claim bonus rider that can be added to this rider, so we should be able to respond to various needs of customers. We would like to use this medical insurance product as sort of the engine to start our sales in 2021, and with the web virtual sales we should be able to minimize the negative impact or the risk of COVID-19, so we’d like to really use this to harness our sales.

Okay, thanks. Then I guess for Max on the tax rate change, was any of this related to the Trump tax cuts, and then accordingly is there any risk that under a different administration, this tax ruling that you got could be reversed?

No, it’s not related to the Trump tax cuts. This is related to a new regulation issued by the U.S. Treasury and the IRS that came out on September 29.

Okay, thanks.

The next question comes from the line of John Barnidge with Piper Sandler.

How should we be thinking about the permanence of the some of the declines in utilization in the U.S. from maybe changed behavior from COVID, principally maybe telemedicine driving down the benefits ratio?

Well, I think it’s still in limbo in terms of what we’re absolutely sure will happen. Certainly we have seen when, let’s say April-May-June, people were staying inside more, they were not going to the doctor, we saw a drop-off in the claims. The idea of the wellness benefit is to get them back to a doctor, twofold: one, to have utilization of the policy and therefore improved persistency, raise the loss ratio some but also prevent people from--I mean, I have a friend whose wife was diagnosed with a stage 3 cancer, and if they had gone to the doctor as they should have but couldn’t because of COVID, they could have caught it much earlier. So one of the things that we’re watching is to see whether or not there’s a tail on this, and that’s why we’re trying to encourage people to go ahead now and go back to the doctor, use these wellness benefits, get the exams you should get, and hopefully that brings down the tail on the business. We know that it’s already picking back up in terms of people going back to the doctor, but it’s not back to the normal amount that it was running pre-COVID.

Okay, very helpful. The wellness initiative that trimmed 100 basis points on the benefits ratio, has that completely played out or could there be still more to come?

We believe that there could still be more to come there.

Thank you.

The next question comes from the line of Erik Bass with Autonomous Research.

Hi, thank you. Do you intend to let all of the tax benefit drop to the bottom line, and do you see opportunity to either accelerate investment or adjust product pricing to boost growth?

We obviously have multiple initiatives in place in order to drive growth, as Fred outlined, and that is pushing up our expense ratio and has. That’s been in play for the last couple of years, and we see that ongoing. Generally I would characterize this benefit as dropping to the bottom line.

One thing I would add, though, and this goes to the previous question too about how to think about future corporate tax rate changes, is that we do have to be mindful of that. This effectively just creates an even playing field for the way in which we report our effective tax rate and cash tax payments; in other words, we are effectively paying a 21% corporate tax rate as being a U.S. taxpayer at Aflac, and so to the degree there is a change in tax law going forward, we’ll be impacted much like any other corporate taxpayer in the U.S., so we do have to be mindful of that and we’ll be watching that carefully. Having said that, though, there is a very real benefit to us, both cash-wise and effective tax rate for a period of time, including going back and grabbing some cash flows that we had previously paid out in the way of tax payments, so it’s a real benefit that one that you want to be careful about taking into the future, if you believe there could be changes in the corporate tax rate going forward.

Thank you, then can you talk a little bit about the recruiting and licensing backdrop for new agents?

Rich?

Absolutely. First of all, recruiting continues to be a very important part of our element and strategy going forward. We saw improvement in the third quarter compared to the second quarter, and we--you know, at the beginning of 2020 we implemented significant alignment from a compensation program to drive producer growth and to drive recruiting. The anticipation on recruiting for the fourth quarter is we expect to see moderate improvement compared to the second and third quarter, and then as we look to 2021, we’ll clearly talk about that more at the investor conference, but it will be a key part of our strategy.

Got it, thank you.

The next question comes from the line of Humphrey Lee with Dowling & Partners.

Good morning and thank you for taking my questions. My first question is related to the expenses in Japan. I heard that you talked about the ¥1.7 billion for the COVID-related expenses in the quarter, and then also there was ¥2 billion related to the paperless initiatives. But just looking at the sequential increase in expenses, still those two pieces only explain half of the increase, so I was just wondering what’s the other driver for the much higher expenses in the quarter?

The main driver in terms of the expense ratio is the decline in revenues, so you have the increased spending but also the function of lower revenues is impacting the expense ratio.

But I’m just referring to the notional general expense amount of ¥72 billion.

I think much of that has to do with just seasonal dynamics related to direct mail spend as well as other promotional initiatives in the quarter related to--you know, as compared to last year, so I think some of it was just natural fluctuation. The two main drivers, and maybe I would add a third, are not only COVID-related expenses and the paperless initiative, but we also continue to accelerate certain digital investments in the quarter, and those are the primary drivers of just an incremental increase in general operating expenses.

Okay, and then in terms of the Zurich addition in the fourth quarter, how should we think about the size of the premium add, and then also by extension the expense impacts of that platform, and also what’s your expectation on a full year premium basis for that business?

That business has been running at around, I believe in the $75 million to $100 million annualized premium range. As you can expect, that’s a lumpy business because it’s largely a start-up at Zurich and it tends to focus on large accounts. But it’s also a very persistent business, so there’s high persistency with that business, so I would expect on an annualized basis it’s in that range, so it will have a modest impact to annual earned premium. In terms of the overall P&L impact on it, as we mentioned when we announced the transaction, we would expect there to be roughly $0.05 dilution on an annualized basis related to that transaction, and that’s largely because as they are still ramping up the business, their revenue is not enough to offset their cost structure because it’s in a growth mode, and so--and we expect obviously and intend to continue that growth mode going forward, so that’s essentially the nature of the business. It’s modestly dilutive to earnings and modestly accretive to earned premium.

Got it, thank you.

The next question comes from the line of Andrew Kligerman with Credit Suisse.

Hey, good morning. My first question is around the benefits ratio, and I’m wondering as we look out in the U.S. at 48.3, down from 49.1 year-over-year, and then of course 44.3 quarter-over-quarter, have we reached kind of a stable zone now? How would you expect it to trend over the course of the next several quarters?

Well in general, we would expect it to trend up, but really up to previous reported numbers prior to the pandemic, and that’s simply because of what Dan outlined in his comments, that there will be naturally a gradual increase in utilization but really back to normal levels, and still overall favorable relative to going back in history, so you’ll see it trend up. Wellness related impacts will subside, we certainly hope, but frankly we’re monitoring, as you can imagine given the news, COVID related cases, but overall we would expect utilization to find its more normal levels over time. We are bringing on businesses that tend to have higher benefit ratios and lower expense ratios - network dental and vision, for example, and then of course group benefits, so over time you’ll eventually have a bit of a mix play in our benefit ratio to be aware of, but that’s unlikely to be material certainly over the next several quarters and in 2021. But you’ll see that play out over time and we’ll of course be able to report that out and let you know what’s influencing the benefit ratio and expense ratio.

Great. Earlier in the year, you provided a credit stress scenario of about $680 million of credit losses. Has that changed, improved, worsened? What’s the outlook there, and what are you seeing into 2021?

Eric, why don’t you take that?

Sure thing, thank you, Andrew. Naturally we continue to analyze our portfolio with stress scenarios, inclusive of how our portfolio actually performed over these past six months, and looking forward including assumptions about a second wave and economic and market impacts. In fact, our portfolio has performed very well through the first part of the pandemic and better than expected relative to our stress test. In addition, as you may recollect, in the second quarter we did some marginal de-risking and risk reduction, and there were particular names in the stress test that in essence were impacted or went away. Having said that, we’re completing our newest stress test and intend on presenting that at this upcoming FAB, so if you can be patient for about another month, you’ll see some of the new results.

Got it, thank you.

The final question comes from the line of Tom Gallagher with Evercore ISI.

Good morning. First question, Max, can you give a sense for how the cash tax benefits will compare to the reduction in the GAAP tax rate, and how we should think about that playing out over time?

Cash taxes will always be volatile, and there will be timing differences between our GAAP and our cash taxes, but over time I would expect them to have about the same impact from this change in tax regulation.

Would you expect there to be a meaningful difference in the first couple of years and converge over time, or is it going to be, would you say, directionally similar with some volatility around it, if you know what I mean?

Yes, it would be the latter. There will not any material, significant difference, and certainly not over as long period as a number of years. It’s more the latter, where we might in a short term have some timing differences, but generally speaking we would expect our cash taxes to come down as well.

Got you, and then my follow-up is can you--just given the increase in the benefit ratio in Japan this quarter, the 150 basis points to 200 basis points, can you talk about--and I know you had referenced that was somewhat related to the slowdown in sales and the impact of lapse and reissue, can you talk--given that sales are likely to remain at least somewhat lower relative to historical levels, can you talk about whether you would still expect to see the broader trend of benefit ratio improving here over the next couple of years, or are we likely to see that maybe go the other way?

Todd, why don’t you take a crack at that?

Okay, thanks Max. Really when we look forward for our persistency, and as Max alluded to, it’s totally related to sales activity, and about 80 basis points in the benefit ratio for the quarter is attributed to lack of what I will call lapse in reissue activity. As we introduce product in the first quarter, I would expect that to pick up somewhat for the medical block, so I would really anticipate as we go through next year that you see more of a normalized termination rate, which will lead to a more normal looking benefit ratio, especially as it pertains to the policy reserve aspect of it.

Got you, and Todd, would you still expect the broader trend over multiple years of improvement in the benefit ratio?

I think as we see claims come in and our trends that we have in our cancer and medical blocks, that will be reflected in the benefit ratio going forward.

Okay, thanks.

Tom, we will address some of the underlying drivers in terms of hospitalizations and duration of hospital stays, etc. at FAB, so we’ll give you a little bit more insight into that.

Thank you.

That leads us to the top of the hour. Before concluding, I just wanted to remind you that we have combined our financial analyst briefing and our 2021 outlook call into a special webcast event on the morning of November 19 at 8:00 am Eastern time. For more details, please reach out to Investor Relations here, and we thank you all for joining us today, and look forward to speaking with you soon and wish you all continued good health. Thank you.

This concludes today’s call. Everyone may now disconnect.